135 related articles for article (PubMed ID: 2544741)
1. Loss of leukoregulin up-regulation of natural killer but not lymphokine-activated killer lymphocytotoxicity in human papillomavirus 16 DNA-immortalized cervical epithelial cells.
Furbert-Harris PM; Evans CH; Woodworth CD; DiPaolo JA
J Natl Cancer Inst; 1989 Jul; 81(14):1080-5. PubMed ID: 2544741
[TBL] [Abstract][Full Text] [Related]
2. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
3. Cytokine modulation of immune defenses in cervical cancer.
Evans CH; Flugelman AA; DiPaolo JA
Oncology; 1993; 50(4):245-51. PubMed ID: 8388555
[TBL] [Abstract][Full Text] [Related]
4. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.
Wu R; Coleman N; Stanley M
Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
6. Spermine-directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokine-activated killer lymphocyte cytotoxicity.
Evans CH; Lee TS; Flugelman AA
Nat Immun; 1995; 14(3):157-63. PubMed ID: 8832899
[TBL] [Abstract][Full Text] [Related]
7. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
Manning LS; Bowman RV; Darby SB; Robinson BW
Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
9. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
10. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
11. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
12. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
13. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric evaluation of leukoregulin as an intrinsic molecular mediator of natural killer lymphocyte cytotoxicity.
Evans CH; Heinbaugh JA; Ransom JH
Lymphokine Res; 1987; 6(4):277-97. PubMed ID: 2448552
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
16. Differential response of normal and HPV immortalized ectocervical epithelial cells to B[a]P.
Sizemore N; Mukhtar H; Couch LH; Howard PC; Rorke EA
Carcinogenesis; 1995 Oct; 16(10):2413-8. PubMed ID: 7586144
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
18. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
19. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
20. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes.
Creek KE; Geslani G; Batova A; Pirisi L
Adv Exp Med Biol; 1995; 375():117-35. PubMed ID: 7645423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
